Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with pemetrexed and carboplatin for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no EGFR or ALK positive mutations.
This is written in the approval document as:
Pembrolizumab is indicated in combination with PEMEtrexed and CARBOplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations
Citation
Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/568.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Pembrolizumab, Pemetrexed |